Alecensa (alectinib) - Warning and precaution and specific dose modification guidance for management of haemolytic anaemia

A Dear Healthcare Professional Letter has been issued by F. Hoffmann-La Roche to inform healthcare professionals of the specific dose modification guidance for the management of haemolytic anaemia associated with the use of Alecensa (alectinib). This is in response to a recent cumulative analysis of haemolytic anaemia cases which showed that dose modification of Alecensa led to improvement of the majority of haemolytic anaemia events with reported outcome. Healthcare professionals are advised to withhold Alecensa and initiate appropriate laboratory testing, if the haemoglobin concentration is below 10 g/dl and haemolytic anaemia is suspected. If haemolytic anaemia is confirmed, healthcare professionals are advised to withhold Alecensa treatment until event resolution and resume at a reduced dose, or permanently discontinue Alecensa. The local package insert for Alecensa is being updated with the recommendations. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Nov 2021

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.